(English)
Chime Biologics at BIO Equity Europe 2026
---Turning AI into Biologics Reality Amid the New Global Biopharma Landscape
At this year’s BIO Equity Europe discussions, one message resonated consistently across presentations, panels, and investor conversations: the global biotechnology industry is entering a new era defined by artificial intelligence, accelerated innovation efficiency, and strategic global collaboration.
Representing Chime Biologics, Board Director and CEO Jimmy Wei shared the company’s vision in a featured presentation titled “Turning AI into Biologics Reality”, highlighting how Chime Biologics is integrating China’s rapidly advancing AI ecosystem into end-to-end biologics development and manufacturing capabilities.
AI Is Reshaping the Biologics Industry Faster Than Expected
Jimmy opened the session by reflecting on what Morgan Stanley described as China’s “DeepSeek Moment” in 2025, a symbolic turning point demonstrating the explosive acceleration of AI capabilities across China’s technology ecosystem.
Just one year later, the momentum has evolved beyond software and computation into real-world industrial execution, including AI-powered humanoid robotics, automated systems, and increasingly sophisticated AI-enabled scientific platforms. This unprecedented pace of iteration is now fundamentally transforming the way biologics are discovered, developed, and manufactured.
Jimmy emphasized that while AI-generated molecular design has captured significant industry attention, the true bottleneck in biologics innovation remains the translation from computational creativity into robust wet-lab validation, scalable CMC development, and commercial manufacturing.
“AI can design promising molecules in days,” Jimmy noted during the discussion. “But transforming those molecules into manufacturable biologics with speed, quality, regulatory readiness, and commercial scalability requires an entirely different level of execution capability.”
From AI Discovery to Clinical Reality
A central theme of the presentation was how Chime Biologics is building an integrated “Chime AI Platform” to bridge this critical gap between AI discovery and biologics reality.
The platform integrates multiple layers of AI-enabled capabilities across the biologics development value chain, including:
- AI-assisted protein design
- AI-guided site-specific integration cell line development
- AI-enabled bioprocess optimization
- AI-powered manufacturing digitalization and automation
Through collaborations with leading AI biologics innovators such as Earendil Labs, and Vibrant Therapeutics, Chime Biologics has supported the advancement of more than 20 AI-discovered biologics molecules, several already in clinical development, positioning the company among the global leading biologics CDMOs in AI-enabled biologics programs.
The presentation also highlighted that Chime Biologics has developed full-stack capabilities specifically designed to overcome the unique manufacturability challenges frequently associated with AI-generated molecules, including stability optimization, process robustness, analytical characterization, and scalable GMP production.
One particularly notable benchmark shared during the session demonstrated the potential compression of development timelines:
- Traditional biologics discovery and IND-enabling CMC development: approximately 24–33 months
- Chime AI Platform-powered CMC acceleration: approximately 10.5 months
This dramatic reduction in development timelines reflects the convergence of three structural advantages increasingly emerging within China’s AI in biopharma ecosystem:
- Cost-effective large-scale computing power from sufficient electricity
- Rapid evolution of AI large models fueled by extensive datasets from large population
- Highly efficient wet-lab validation and manufacturing execution capabilities
AI-Powered Innovation Extending into ADC Platforms
Beyond monoclonal antibodies and recombinant proteins, Jimmy also introduced Chime Biologics’ next-generation AI-powered ADC platform technologies, including:
- Novel enzyme-free site-specific conjugation technologies
- Dual payload ADC platforms
- DAR enrichment strategies
These proprietary technologies are intended to improve ADC homogeneity, stability, efficacy, and manufacturing robustness while enabling increasingly sophisticated therapeutic designs for future oncology pipelines.
China’s Biotech Ecosystem Is Evolving from “Fast Follower” to Global Innovation Engine
Panel discussions after Jimmy’s presentation brought together leading global investors and biopharma executives including:
- James Huang, Founder & Managing Partner at Panacea Capital
- Zhizhong Joel Y., Partner at Sofinnova Partners
- Alicia Hong, VP Business Development Asia at BioNTech SE
- Sue Yao, Co-Head of Licensing & Business Development at Kelun-Biotech / Klus Pharma Inc.
Across the discussions, panelists highlighted the accelerating momentum of China licensing-out activities and the increasing global competitiveness of Chinese biopharma innovation.
The panelists collectively emphasized that China’s biotech ecosystem continues to evolve at remarkable speed, driven by advances in AI infrastructure, biologics engineering, translational research, and manufacturing efficiency. At the same time, they noted that geopolitical volatility is reshaping global partnering strategies, making resilient and globally integrated partners increasingly critical. In this environment, CDMOs with broad international presence and capabilities extending beyond CMC into regulatory affairs, financing connectivity, licensing support, and strategic business development are becoming essential partners for biotech companies seeking to accelerate innovation while managing global risks.
Looking Ahead
BIO Equity Europe 2026 made one reality increasingly clear: AI is no longer a future concept for biotechnology. It is rapidly becoming an operational and industrial capability that is reshaping how biologics are discovered, developed, manufactured, and commercialized.
As the global biotech industry enters this next chapter, Chime Biologics remains committed to serving as a trusted strategic partner helping innovators worldwide expedite and de-risk their biologics pipelines through the convergence of AI technology, manufacturing excellence, and global collaboration.
About Chime Biologics
Chime Biologics is a leading global CDMO, focused on ensuring our customers' success in delivering innovative biologics as well as biosimilars to patients across the world. Chime Biologics can support customers end to end, from pre-clinical support and cell line development through to clinical and commercial manufacturing of drug substance and drug product. Employing our state-of-the-art capabilities in our Europe Innovation Hub (Basel, CH), China Innovation Hub (Shanghai, CN), Development & Manufacturing Campus (Wuhan, CN) and proven success in supporting our clients with their clinical and commercial authorizations across the globe, Chime Biologics is a true end-to-end solution provider for the biologics industry. With over 600 skilled employees, we share a common goal to make cutting-edge biologics affordable and accessible to patients worldwide, fulfilling our commitment to improving human health globally.
For more information, please visit www.chimebiologics.com.
